Q4 beat and long-term guidance upgrade welcomed by the markets
06/02/25 -"The Q4 results exceeded the street’s expectations, while the 2025 outlook was in line with consensus estimates. Moreover, the firm raised its longer-term sales ambition, despite key HIV patent ..."
Pages
70
Language
English
Published on
06/02/25
You may also be interested by these reports :
04/08/26
Imagine a restaurant having to serve its customers by ordering outside food. We cannot resist drawing parallels between this hypothetical scenario ...
03/08/26
Astra’s media-reported merger/acquisition talks with Bristol Myers Squibb (BMS) entail worries for Astra’s shareholders – considerable overlapping ...
30/07/26
Ipsen demonstrated robust performance in Q2, exceeding market expectations, which led to an upgraded 2026 guidance. While we may adjust our estimates ...
30/07/26
Bachem released its 1H26 results on 30 July 2026, delivering a strong operating performance for the half. Margins were affected by higher operating ...